Karkinos Healthcare has entered into a strategic partnership with SOPHiA GENETICS, solidifying their commitment to revolutionizing cancer diagnosis and treatment in India.

The formalized Memorandum of Understanding (MOU) establishes a collaborative effort to advance genomic solutions and data-driven medicine, particularly emphasizing the accessibility of personalized cancer treatments.

CEO and Co-founder of SOPHiA GENETICS, Dr. Jurgi Camblong, expressed the significance of the collaboration, stating, "Our partnership with Karkinos is a monumental occasion that brings together two organizations dedicated to democratising advanced access to underserved communities. We aim to improve health outcomes for patients by equipping local health organizations with the technology needed to make data-driven decisions."

Dr. R Venkataramanan, Founder and CEO of Karkinos Healthcare, highlighted the alliance as a pivotal step forward in their mission to democratize advanced cancer care. "Through this partnership, we will harness the power of genomics to improve diagnosis, treatment, and management of cancer, especially for the underprivileged and underserved populations in India."

The collaboration will leverage the capabilities of the SOPHiA DDM Platform, utilizing advanced analysis of genomic variants and integrating artificial intelligence and machine learning algorithms.

This approach aims to accelerate research and enhance the workflow for diagnosing various cancers, including myeloid cancer, lymphoma, and solid tumors such as ovarian, prostate, breast, and lung cancers.

The partnership signifies a united effort to propel genomic advancements into the forefront of oncology care, with a shared commitment to address complex cancer cases and improve healthcare outcomes for diverse populations, marking a significant stride in the field of cancer research and treatment in India.